News

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023…

1 year ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

1 year ago

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…

1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical…

1 year ago

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical…

1 year ago

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

1 year ago

Lexicon Elects Diane E. Sullivan to Board of Directors

Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of DirectorsTHE WOODLANDS, Texas, July…

1 year ago

STRATA Skin Sciences to Report Second Quarter 2023 Financial Results on August 9, 2023

HORSHAM, Pa., July 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

1 year ago

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development…

1 year ago